Across TCGA pan-cancer cohorts, PRAMEF17 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of PRAMEF17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PRAMEF17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRAMEF17 is over-expressed in tumor.

HNSC are the cancer types where PRAMEF17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.032	.024	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: PRAMEF17 RNA expression & survival · all PRAMEF17 data types